AGRX Agile Therapeutics Inc.

2.05
+0.04  (+2%)
Previous Close 2.01
Open 1.95
Price To Book 3.87
Market Cap 178,473,625
Shares 87,060,305
Volume 1,486,602
Short Ratio
Av. Daily Volume 4,368,043
Stock charts supplied by TradingView

NewsSee all news

  1. Agile Therapeutics, Inc. (Nasdaq: AGRX) to Ring Nasdaq Stock Market Closing Bell on Wednesday, February 26, 2020

    PRINCETON, N.J., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a forward-thinking women's healthcare company, today announced that the Company will visit the Nasdaq MarketSite in Times

  2. Agile Therapeutics Announces Pricing of $45 Million Underwritten Public Offering of Common Stock

    PRINCETON, N.J., Feb. 21, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today announced the pricing of its underwritten public offering of 15 million shares of its

  3. Agile Therapeutics Announces Proposed Underwritten Public Offering of Common Stock

    PRINCETON, N.J., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today announced that it intends to offer and sell shares of its common stock in an underwritten

  4. Agile Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results

    Current Cash and Cash Equivalents Expected to Meet Projected Operating Requirements through End of 2020 Twirla®, Company's Lead Product Candidate, Receives FDA Approval Company Plans to Commence Distributing Product to

  5. FDA Approves Agile Therapeutics, Inc.'s Twirla® (levonorgestrel and ethinyl estradiol) Transdermal System – A New Weekly Contraceptive Patch Delivering a 30 mcg Daily Dose of Estrogen and 120 mcg Daily Dose of Progestin

    Twirla® is a new non-daily, non-invasive contraceptive approved in the U.S. PRINCETON, N.J., Feb. 14, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX) (Agile or the Company), a forward-thinking

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

FDA Approval announced February 14, 2020.
Twirla
Contraceptive patch

Latest News

  1. Agile Therapeutics, Inc. (Nasdaq: AGRX) to Ring Nasdaq Stock Market Closing Bell on Wednesday, February 26, 2020

    PRINCETON, N.J., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a forward-thinking women's healthcare company, today announced that the Company will visit the Nasdaq MarketSite in Times

  2. Agile Therapeutics Announces Pricing of $45 Million Underwritten Public Offering of Common Stock

    PRINCETON, N.J., Feb. 21, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today announced the pricing of its underwritten public offering of 15 million shares of its

  3. Agile Therapeutics Announces Proposed Underwritten Public Offering of Common Stock

    PRINCETON, N.J., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today announced that it intends to offer and sell shares of its common stock in an underwritten

  4. Agile Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results

    Current Cash and Cash Equivalents Expected to Meet Projected Operating Requirements through End of 2020 Twirla®, Company's Lead Product Candidate, Receives FDA Approval Company Plans to Commence Distributing Product to

  5. FDA Approves Agile Therapeutics, Inc.'s Twirla® (levonorgestrel and ethinyl estradiol) Transdermal System – A New Weekly Contraceptive Patch Delivering a 30 mcg Daily Dose of Estrogen and 120 mcg Daily Dose of Progestin

    Twirla® is a new non-daily, non-invasive contraceptive approved in the U.S. PRINCETON, N.J., Feb. 14, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX) (Agile or the Company), a forward-thinking

  6. Agile Therapeutics, Inc. Enters into up to $35 Million Loan Facility with Perceptive Advisors

    Funding to Support the Company's Commercialization Plans for Twirla® PRINCETON, N.J., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today announced that it has

  7. Agile Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco

    PRINCETON, N.J., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today announced that the company will present at the 38th Annual J.P. Morgan Healthcare

  8. Agile Therapeutics Strengthens Commercial Leadership Team

    PRINCETON, N.J., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today announced the appointment of Kimberly Whelan as Vice President of Market Access. Ms. Whelan

  9. Agile Therapeutics to Present at Biotech Showcase™ 2020 in San Francisco

    PRINCETON, N.J., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today announced that it has scheduled a company presentation at Biotech Showcase™ 2020, to be

  10. Agile Therapeutics Announces FDA Extension of Twirla® NDA Review Period

    PRINCETON, N.J., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription

  11. Agile Therapeutics Announces Favorable Outcome of FDA Advisory Committee Meeting for its Investigational Transdermal Contraceptive Patch, Twirla® (AG200-15)

    Committee Votes 14 to 1, with 1 Abstention, in Favor of Approval PRINCETON, N.J., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, announced a positive outcome

  12. Agile Therapeutics to Present at Upcoming Investor Conferences

    PRINCETON, N.J., Sept. 06, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, announced today that its Chairman and Chief Executive Officer, Al Altomari, will present at